An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…
The ACR’s response to the Centers for Medicare & Medicaid Services addresses the likely harm of the proposed conversion factor on the solvency and stability of rheumatology practices. The comments also include recommendations on complex drug administration coding, inflation-adjusted drug rebates and extending telehealth flexibilities.
ACR staff can help members navigate questions on all areas of practice management.
If you’re headed to Washington, D.C., this November for ACR Convergence 2024, plan now to schedule meetings with your members of Congress. Your voice as a constituent can help your lawmakers understand which policies are good for healthcare as they consider a critical end-of-year funding package.
The updated draft guidance, released in June, would accept an assessment of why data provided meet the switching standard to demonstrate interchangeability of biosimilars
Revisions of the handbook to reflect an evolving healthcare landscape are underway, led by the Committee on Rheumatologic Care, Community Practice Council and Insurance Subcommittee. The first new chapters will be available in fall 2024.
The ACR is seeking a representative to the Young Physician Section of the AMA House of Delegates who will join the ACR’s delegation at future HOD meetings and advance issues important to rheumatology.
The ACR was fortunate to participate in the Association for Women in Rheumatology’s 2024 Annual Meeting in Orlando. As this relationship grows every year, the AWIR and ACR are working together to build a sustainable and inclusive rheumatology community for the future.
New members include rheumatology state societies, specialty partners in gastroenterology and patient-facing organizations representing digestive and inflammatory diseases. The ACR and coalition partners are strategizing additional steps to ensure practices receive adequate reimbursement for biosimilars.
The recently introduced Physician Fee Stabilization Act (S. 4935) would raise the budget neutrality threshold from $20 million to $53 million and help alleviate the annual uncertainty providers face surrounding Medicare reimbursement rates.